<DOC>
	<DOCNO>NCT00144781</DOCNO>
	<brief_summary>The main purpose study evaluate difference pharmacodynamic response 4 Aldurazyme® ( laronidase ) dose regimens patient Mucopolysaccharidosis I ( MPS I ) .</brief_summary>
	<brief_title>A Dose-optimization Study Aldurazyme® ( Laronidase ) Patients With Mucopolysaccharidosis I ( MPS I ) Disease</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<criteria>Have document diagnosis MPS I , confirm measurable clinical sign symptom MPS I , document fibroblast leukocyte αLiduronidase enzyme activity level le 10 % low limit normal range measure laboratory . Weigh least 12.5 kg . Have serum creatinine blood urea nitrogen ( BUN ) value within age appropriate normal range . Provide sign , write informed consent prior protocolrelated procedure perform . Consent legally authorize guardian ( ) ( ) require patient 18 year . If patient 18 year old understand consent , write informed consent require patient authorized guardian ( ) . Have previously receive Aldurazyme® ( laronidase ) . Have suspect hypersensitivity Aldurazyme® ( laronidase ) know hypersensitivity component infusion solution . Have previously undergo hematopoietic stem cell transplantation ( HSCT ; i.e. , bone marrow [ BMT ] , peripheral blood , umbilical cord blood ) major organ transplantation . Have medical condition , serious intercurrent illness , extenuate circumstance may interfere study compliance include prescribed evaluation followup activity , except 6MWT . ( Note : All patient may capable perform 6MWT due age and/or maturity level . Exemption perform 6MWT must obtain write investigator sponsor 's medical monitor prior enrollment ) . Have acute illness require surgical intervention , and/or anticipates surgery study participation , and/or surgery within 30 day prior study enrollment . Have receive investigational drug within 30 day prior study enrollment . Is pregnant lactate . Female patient childbearing potential must negative pregnancy test [ urine βhuman chronic gonadotropin ( hCG ) ] entry ( prior first infusion ) . Note : All female patient childbearing potential sexually mature male must advise use medically accept method contraception throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>